MCID: HMP007
MIFTS: 62

Hemophilia

Categories: Blood diseases, Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Hemophilia

MalaCards integrated aliases for Hemophilia:

Name: Hemophilia 77 54 26 38 30 44 3 64 64
Hemophilia, Hereditary 26
Hemophilia, Familial 26
Hemophilia, Nos 74
Hemophilia a 74
Haemophilia 26

Classifications:



External Ids:

KEGG 38 H00219

Summaries for Hemophilia

MedlinePlus : 44 Hemophilia is a rare disorder in which the blood does not clot normally. It is usually inherited. Hemophilia usually occurs in males. If you have hemophilia, you have little or no clotting factor. Clotting factor is a protein needed for normal blood clotting. Without it, you may bleed for a long time after an injury or accident. You also may bleed into your knees, ankles, and elbows. Bleeding in the joints causes pain and, if not treated, can lead to arthritis. Bleeding in the brain, a very serious complication of hemophilia, requires emergency treatment. The main symptoms of hemophilia are excessive bleeding and easy bruising. Blood tests can tell if you have it. The main treatment is injecting the missing clotting factor into the bloodstream. You may need it on a regular basis, or just when bleeding occurs. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Hemophilia, also known as hemophilia, hereditary, is related to acquired hemophilia and acquired hemophilia a, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Hemophilia is F8 (Coagulation Factor VIII), and among its related pathways/superpathways are Complement and coagulation cascades and ECM-receptor interaction. The drugs Thrombin and Anti-inhibitor coagulant complex have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and testes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Genetics Home Reference : 26 Hemophilia is a bleeding disorder that slows the blood clotting process. People with this condition experience prolonged bleeding or oozing following an injury, surgery, or having a tooth pulled. In severe cases of hemophilia, continuous bleeding occurs after minor trauma or even in the absence of injury (spontaneous bleeding). Serious complications can result from bleeding into the joints, muscles, brain, or other internal organs. Milder forms of hemophilia do not necessarily involve spontaneous bleeding, and the condition may not become apparent until abnormal bleeding occurs following surgery or a serious injury.

NIH Rare Diseases : 54 Hemophilia is a bleeding disorder that slows the blood clotting process. People with this disorder experience prolonged bleeding following an injury, surgery, or having a tooth pulled. In severe cases, heavy bleeding occurs after minor trauma or in the absence of injury. Serious complications can result from bleeding into the joints, muscles, brain, or other internal organs. The major types of this disorder are hemophilia A and hemophilia B. Although the two types have very similar signs and symptoms, they are caused by mutations in different genes. People with an unusual form of hemophilia B, known as hemophilia B Leyden, experience episodes of excessive bleeding in childhood, but have few bleeding problems after puberty. Another form of the disorder, acquired hemophilia, is not caused by inherited gene mutations.

CDC : 3 Hemophilia is usually an inherited bleeding disorder in which the blood does not clot properly. People with hemophilia can live full lives and enjoy most of the activities that other people do. If you have hemophilia, or know someone who does, it’s important to learn how to stay as healthy as possible.

PubMed Health : 64 About hemophilia: Hemophilia (heem-o-FILL-ee-ah) is a rare bleeding disorder in which the blood doesn't clot normally.If you have hemophilia, you may bleed for a longer time than others after an injury. You also may bleed inside your body (internally), especially in your knees, ankles, and elbows. This bleeding can damage your organs and tissues and may be life threatening.

Wikipedia : 77 Haemophilia is a mostly inherited genetic disorder that impairs the body''s ability to make blood clots,... more...

Related Diseases for Hemophilia

Diseases in the Hemophilia family:

Hemophilia a Hemophilia B
Acquired Hemophilia Acquired Hemophilia a

Diseases related to Hemophilia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 515, show less)
# Related Disease Score Top Affiliating Genes
1 acquired hemophilia 34.0 F3 F8 F9
2 acquired hemophilia a 34.0 F3 F8 F9
3 hemophilia a 33.6 F3 F7 F8 F9 VWF
4 hemophilia b 33.4 F2 F3 F7 F8 F9
5 factor xi deficiency 32.5 F2 F3 F9
6 von willebrand's disease 32.3 F2 F3 F8 F9 VWF
7 von willebrand disease, type 3 32.1 F3 F8 VWF
8 factor viii deficiency 32.1 F2 F8 LMAN1 MCFD2 VWF
9 factor v and factor viii, combined deficiency of, 2 31.9 F8 LMAN1 MCFD2
10 hemarthrosis 31.8 F7 F8 F9 VWF
11 von willebrand disease, type 2 31.7 F3 F7 F8 VWF
12 thrombophilia 31.3 F2 F3 F8 F9 VWF
13 von willebrand disease, type 1 31.1 F2 F3 F8 VWF
14 thrombosis 30.6 F2 F3 F7 F8 F9 TFPI
15 compartment syndrome 30.3 F2 F8
16 factor xii deficiency 30.0 F3 F9
17 purpura 30.0 F2 F3 VWF
18 cardiac tamponade 29.8 F2 F8 F9
19 thrombophilia due to thrombin defect 29.7 F2 F3 F8 VWF
20 thrombasthenia 29.7 F2 F3
21 femoral neuropathy 29.6 F2 F3
22 thrombotic thrombocytopenic purpura 29.5 F3 VWF
23 varicose veins 29.5 F2 VWF
24 squamous cell papilloma 29.5 F2 F3
25 factor vii deficiency 29.4 F2 F3 F7 F8 F9
26 intracranial hypertension 29.4 F2 F3
27 portal vein thrombosis 29.4 F2 F7
28 myocardial infarction 29.3 F2 F3 F7 F8 VWF
29 vascular disease 29.3 F2 F3 VWF
30 antiphospholipid syndrome 29.3 F2 F3 VWF
31 disseminated intravascular coagulation 29.3 F2 F3 F7 F9
32 prothrombin deficiency 29.3 F2 F3 F7
33 afibrinogenemia, congenital 29.2 F2 F3 VWF
34 afibrinogenemia 29.2 F2 F3 F8 VWF
35 essential thrombocythemia 29.2 F2 F3 VWF
36 pulmonary embolism 29.2 F2 F3 F9 VWF
37 thrombocytosis 29.2 F2 F3
38 heart disease 29.0 F2 F3 F7 F8 VWF
39 hemorrhagic disease 28.8 F2 F3 F7 F8 F9 VWF
40 stroke, ischemic 28.8 F2 F3 F7 VWF
41 glanzmann thrombasthenia 28.7 F2 F3 F8 F9 VWF
42 factor x deficiency 28.2 F2 F3 F7 F9 TFPI VWF
43 factor v deficiency 27.3 F2 F3 F7 F8 F9 LMAN1
44 hemophilia a with vascular abnormality 12.1
45 factor v and factor viii, combined deficiency of, 1 11.2
46 hepatitis 10.6
47 hepatitis c 10.5
48 hepatitis c virus 10.3
49 arthritis 10.3
50 joint disorders 10.3
51 arthropathy 10.3
52 factor xiii deficiency 10.3 F3 F8
53 fainting 10.3 F8 VWF
54 cerebral arteritis 10.3 F8 VWF
55 acquired immunodeficiency syndrome 10.2
56 grange syndrome 10.2 F3 VWF
57 leukemia 10.2
58 human immunodeficiency virus infectious disease 10.2
59 intermediate coronary syndrome 10.2 F3 VWF
60 malignant skin fibrous histiocytoma 10.2 F7 F9
61 coronary thrombosis 10.2 F3 VWF
62 rheumatoid arthritis 10.2
63 thrombocytopenia 10.2
64 lymphangiosarcoma 10.1 F8 VWF
65 livedoid vasculitis 10.1 F2 F8
66 cerebral falx meningioma 10.1 F2 F3
67 thrombophlebitis 10.1 F2 F8
68 leech infestation 10.1 F2 F3
69 intestinal impaction 10.1 F2 F3
70 post-thrombotic syndrome 10.1 F2 F8
71 cerebral sinovenous thrombosis 10.1 F2 F3
72 giant hemangioma 10.1 F2 F3
73 malignant dermis tumor 10.1 F7 F9
74 sagittal sinus thrombosis 10.1 F2 F3
75 blue toe syndrome 10.1 F2 F3
76 hantavirus pulmonary syndrome 10.1 F2 F3
77 marantic endocarditis 10.1 F2 F3
78 vascular hemostatic disease 10.1 F2 F3
79 splenic disease 10.1 F2 F3
80 purpura fulminans 10.1 F2 F3
81 human immunodeficiency virus type 1 10.1
82 thalassemia 10.1
83 hepatic infarction 10.1 F2 F3
84 retinal artery occlusion 10.1 F2 F8
85 peripheral vertigo 10.1 F2 F3
86 blood protein disease 10.1 F2 F3
87 acquired von willebrand syndrome 10.1 F8 F9 VWF
88 endocardium disease 10.1 F2 F3
89 active peptic ulcer disease 10.1 F2 VWF
90 branch retinal artery occlusion 10.1 F2 F3
91 intracranial thrombosis 10.1 F3 F8 VWF
92 liver disease 10.1
93 lupus erythematosus 10.1
94 mesenteric vascular occlusion 10.1 F2 F7
95 analbuminemia 10.0 F2 F3
96 pulmonary artery disease 10.0 F2 F3
97 hepatocellular carcinoma 10.0
98 systemic lupus erythematosus 10.0
99 hepatitis b 10.0
100 hydrocephalus 10.0
101 spotted fever 10.0 F2 VWF
102 protein s deficiency 10.0 F2 F3
103 protein c deficiency 10.0 F2 F9
104 coumarin resistance 10.0 F9 MCFD2
105 aging 10.0
106 lymphoma 10.0
107 synovitis 10.0
108 pneumonia 10.0
109 bullous pemphigoid 10.0
110 fournier gangrene 10.0 F2 F3 F8
111 alcohol-related birth defect 10.0 F2 F3 F8
112 vein disease 10.0 F2 F3 F8
113 venous insufficiency 10.0 F2 VWF
114 diabetes mellitus 10.0
115 colitis 10.0
116 esophageal varix 10.0
117 arteriovenous malformation 10.0
118 juvenile rheumatoid arthritis 10.0
119 carotid stenosis 10.0 F7 TFPI
120 bone disease 9.9
121 placental insufficiency 9.9 F2 F3
122 intermittent claudication 9.9 F2 VWF
123 brachydactyly, type d 9.9 F2 F8 VWF
124 leukemia, chronic lymphocytic 2 9.9
125 leukemia, chronic lymphocytic 9.9
126 myeloma, multiple 9.9
127 muscular dystrophy, duchenne type 9.9
128 osteoarthritis 9.9
129 ulcerative colitis 9.9
130 lymphocytic leukemia 9.9
131 hemopericardium 9.9
132 nephrotic syndrome 9.9
133 thrombocytopenia due to platelet alloimmunization 9.9
134 pancreatitis 9.9
135 septic arthritis 9.9
136 muscular dystrophy 9.9
137 congenital hydrocephalus 9.9
138 hemophilic arthropathy 9.9
139 leukemia, b-cell, chronic 9.9
140 bernard-soulier syndrome 9.9 F2 F8 VWF
141 qualitative platelet defect 9.9 F2 F3 VWF
142 korean hemorrhagic fever 9.9 F2 F3 VWF
143 hepatic vascular disease 9.9 F2 F3 VWF
144 peripheral vascular disease 9.9 F2 F3 VWF
145 hellp syndrome 9.9 F2 F3 VWF
146 adenoma 9.9
147 dengue hemorrhagic fever 9.9 F2 F3
148 anterior cranial fossa meningioma 9.9 F2 F3 F7
149 arteries, anomalies of 9.9
150 prostate cancer 9.9
151 thrombocytopenic purpura, autoimmune 9.9
152 lung cancer 9.9
153 cystic fibrosis 9.9
154 prostate cancer, hereditary, 8 9.9
155 anxiety 9.9
156 prostate cancer, hereditary, 6 9.9
157 beta-thalassemia 9.9
158 acute myocardial infarction 9.9
159 cerebral hemorrhage 9.9
160 atrial fibrillation 9.9
161 pneumocystosis 9.9
162 hemoglobinopathy 9.9
163 turner syndrome 9.9
164 budd-chiari syndrome 9.8 F2 F3 F7
165 pre-eclampsia 9.8 F2 F3 VWF
166 autoimmune hepatitis 9.8
167 dental caries 9.8
168 pituitary adenoma 9.8
169 intestinal obstruction 9.8
170 sickle cell disease 9.8
171 aortic coarctation 9.8
172 dysphagia 9.8
173 cerebrovascular disease 9.8 F2 F7 VWF
174 aortic aneurysm, familial abdominal, 1 9.8
175 esophageal cancer 9.8
176 frasier syndrome 9.8
177 myositis 9.8
178 adrenoleukodystrophy 9.8
179 asthma 9.8
180 sickle cell anemia 9.8
181 gastrointestinal stromal tumor 9.8
182 ichthyosis prematurity syndrome 9.8
183 acute promyelocytic leukemia 9.8
184 gastric cancer 9.8
185 hemorrhage, intracerebral 9.8
186 pulmonary hypertension 9.8
187 coronary artery anomaly 9.8
188 hemolytic anemia 9.8
189 ischemic heart disease 9.8
190 liver cirrhosis 9.8
191 autoimmune pancreatitis 9.8
192 bone resorption disease 9.8
193 mumps 9.8
194 endocarditis 9.8
195 infant gynecomastia 9.8
196 pericardial effusion 9.8
197 gynecomastia 9.8
198 ventricular septal defect 9.8
199 pneumothorax 9.8
200 pericarditis 9.8
201 viral hepatitis 9.8
202 ischemia 9.8
203 retinitis 9.8
204 aortic aneurysm 9.8
205 paraplegia 9.8
206 lymphopenia 9.8
207 myositis ossificans 9.8
208 influenza 9.8
209 lung disease 9.8
210 measles 9.8
211 neuropathy 9.8
212 rubella 9.8
213 pemphigus 9.8
214 adrenomyeloneuropathy 9.8
215 bowenoid papulosis 9.8
216 fibromatosis 9.8
217 depression 9.8
218 head injury 9.8
219 blood platelet disease 9.7 F2 F3 F8 VWF
220 spondyloarthropathy 1 9.6
221 bladder cancer 9.6
222 cerebral cavernous malformations 9.6
223 glioma susceptibility 1 9.6
224 attention deficit-hyperactivity disorder 9.6
225 hypertension, essential 9.6
226 kaposi sarcoma 9.6
227 noonan syndrome 1 9.6
228 pheochromocytoma 9.6
229 popliteal cyst 9.6
230 scleroderma, familial progressive 9.6
231 temporal arteritis 9.6
232 torticollis 9.6
233 trigeminal neuralgia 9.6
234 enterocolitis 9.6
235 wilson disease 9.6
236 thrombophilia, x-linked, due to factor ix defect 9.6
237 46,xy sex reversal 1 9.6
238 retinitis pigmentosa 12 9.6
239 helicobacter pylori infection 9.6
240 salla disease 9.6
241 vitiligo-associated multiple autoimmune disease susceptibility 1 9.6
242 hurler syndrome 9.6
243 coronary heart disease 1 9.6
244 patent ductus arteriosus 1 9.6
245 aural atresia, congenital 9.6
246 ovarian hyperstimulation syndrome 9.6
247 avascular necrosis of femoral head, primary, 1 9.6
248 malaria 9.6
249 bone mineral density quantitative trait locus 8 9.6
250 bone mineral density quantitative trait locus 15 9.6
251 prothrombin deficiency, congenital 9.6
252 dengue virus 9.6
253 aortic valve disease 2 9.6
254 leptin deficiency or dysfunction 9.6
255 melioidosis 9.6
256 cerebral palsy 9.6
257 chronic granulomatous disease 9.6
258 dengue disease 9.6
259 diffuse large b-cell lymphoma 9.6
260 gas gangrene 9.6
261 hereditary hemorrhagic telangiectasia 9.6
262 mantle cell lymphoma 9.6
263 pol iii-related leukodystrophies 9.6
264 inflammatory bowel disease 9.6
265 spastic cerebral palsy 9.6
266 adrenal gland pheochromocytoma 9.6
267 primary hyperparathyroidism 9.6
268 tetanus 9.6
269 diphtheria 9.6
270 dieulafoy lesion 9.6
271 telangiectasis 9.6
272 plasmodium vivax malaria 9.6
273 porphyria 9.6
274 ehlers-danlos syndrome 9.6
275 hyperparathyroidism 9.6
276 biliary atresia 9.6
277 obstructive hydrocephalus 9.6
278 46 xy gonadal dysgenesis 9.6
279 hypothyroidism 9.6
280 impotence 9.6
281 hepatitis d 9.6
282 dermatitis 9.6
283 prostatic adenoma 9.6
284 endometriosis 9.6
285 membranoproliferative glomerulonephritis 9.6
286 kidney cortex necrosis 9.6
287 adenocarcinoma 9.6
288 glioblastoma multiforme 9.6
289 astrocytoma 9.6
290 interstitial lung disease 9.6
291 tracheal stenosis 9.6
292 syringomyelia 9.6
293 thyroiditis 9.6
294 hyperthyroidism 9.6
295 peritonitis 9.6
296 perinatal necrotizing enterocolitis 9.6
297 achalasia 9.6
298 neurofibroma 9.6
299 hypermobile ehlers-danlos syndrome 9.6
300 acute respiratory distress syndrome 9.6
301 catastrophic antiphospholipid syndrome 9.6
302 double outlet left ventricle 9.6
303 dysfibrinogenemia 9.6
304 glioblastoma 9.6
305 lymphomatous thyroiditis 9.6
306 plasmablastic lymphoma 9.6
307 polymyositis 9.6
308 pseudo-turner syndrome 9.6
309 thrombotic thrombocytopenic purpura, acquired 9.6
310 aniridia 1 9.6
311 autoimmune disease 9.6
312 blood group, colton system 9.6
313 burkitt lymphoma 9.6
314 carpal tunnel syndrome 9.6
315 cleft palate, isolated 9.6
316 creutzfeldt-jakob disease 9.6
317 multiple sclerosis 9.6
318 fibromatosis, gingival, 1 9.6
319 fish-eye disease 9.6
320 immunoglobulin a deficiency 1 9.6
321 hemangioma-thrombocytopenia syndrome 9.6
322 pallister-hall syndrome 9.6
323 intussusception 9.6
324 laryngeal adductor paralysis 9.6
325 legg-calve-perthes disease 9.6
326 marfan syndrome 9.6
327 meckel diverticulum 9.6
328 carney complex, type 1 9.6
329 ocular cicatricial pemphigoid 9.6
330 enchondromatosis, multiple, ollier type 9.6
331 osteoporosis 9.6
332 pemphigus vulgaris, familial 9.6
333 proteus syndrome 9.6
334 schizophrenia 9.6
335 small cell cancer of the lung 9.6
336 split-hand/foot malformation 1 9.6
337 tetralogy of fallot 9.6
338 down syndrome 9.6
339 anemia, autoimmune hemolytic 9.6
340 australia antigen 9.6
341 complement component 2 deficiency 9.6
342 crigler-najjar syndrome, type i 9.6
343 lymphoma, hodgkin, classic 9.6
344 moyamoya disease 1 9.6
345 mucopolysaccharidosis, type vii 9.6
346 myasthenia gravis 9.6
347 myelofibrosis 9.6
348 pancreatic cancer 9.6
349 polycythemia vera 9.6
350 retinitis pigmentosa 9.6
351 body mass index quantitative trait locus 11 9.6
352 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 9.6
353 incontinentia pigmenti 9.6
354 leukemia, acute myeloid 9.6
355 body mass index quantitative trait locus 8 9.6
356 caronte 9.6
357 mass syndrome 9.6
358 leber congenital amaurosis 4 9.6
359 lymphoma, non-hodgkin, familial 9.6
360 tricuspid atresia 9.6
361 allergic rhinitis 9.6
362 psoriatic arthritis 9.6
363 body mass index quantitative trait locus 10 9.6
364 body mass index quantitative trait locus 7 9.6
365 aplastic anemia 9.6
366 body mass index quantitative trait locus 14 9.6
367 mononeuropathy of the median nerve, mild 9.6
368 protein z deficiency 9.6
369 hermansky-pudlak syndrome 6 9.6
370 aspergillosis 9.6
371 psoriasis 14, pustular 9.6
372 myelodysplastic syndrome 9.6
373 meconium ileus 9.6
374 membranous nephropathy 9.6
375 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 9.6
376 body mass index quantitative trait locus 18 9.6
377 alacrima, achalasia, and mental retardation syndrome 9.6
378 complement factor b deficiency 9.6
379 cholangiocarcinoma 9.6
380 mucopolysaccharidosis-plus syndrome 9.6
381 body mass index quantitative trait locus 19 9.6
382 deficiency anemia 9.6
383 west syndrome 9.6
384 acute leukemia 9.6
385 arteriovenous fistula 9.6
386 breast reconstruction 9.6
387 cataract 9.6
388 charcot-marie-tooth disease 9.6
389 glomerulonephritis 9.6
390 hemangioma 9.6
391 hematopoietic stem cell transplantation 9.6
392 lymphoblastic lymphoma 9.6
393 neutropenia 9.6
394 osteopetrosis 9.6
395 pemphigus foliaceus 9.6
396 pemphigus vulgaris 9.6
397 retinal vein occlusion 9.6
398 invasive aspergillosis 9.6
399 oculocutaneous albinism 9.6
400 chorioamnionitis 9.6
401 peripheral artery disease 9.6
402 sleep apnea 9.6
403 autism spectrum disorder 9.6
404 pain agnosia 9.6
405 ischemic colitis 9.6
406 scoliosis 9.6
407 persistent hyperplastic primary vitreous 9.6
408 cardiac arrest 9.6
409 mastoiditis 9.6
410 gingival fibromatosis 9.6
411 cytomegalovirus retinitis 9.6
412 chronic neutrophilic leukemia 9.6
413 rickets 9.6
414 protein-losing enteropathy 9.6
415 gastric ulcer 9.6
416 tooth disease 9.6
417 sarcoma 9.6
418 respiratory failure 9.6
419 constrictive pericarditis 9.6
420 chondrocalcinosis 9.6
421 choledocholithiasis 9.6
422 mononeuropathy 9.6
423 patulous eustachian tube 9.6
424 graves' disease 9.6
425 pancytopenia 9.6
426 hepatitis a 9.6
427 hemolytic-uremic syndrome 9.6
428 pyloric stenosis 9.6
429 mycoplasma pneumoniae pneumonia 9.6
430 color blindness 9.6
431 gonadal dysgenesis 9.6
432 angioedema 9.6
433 communicating hydrocephalus 9.6
434 duodenal ulcer 9.6
435 cryptosporidiosis 9.6
436 factitious disorder 9.6
437 epilepsy 9.6
438 melanoma 9.6
439 cholecystitis 9.6
440 pharyngitis 9.6
441 arteriosclerosis 9.6
442 central retinal vein occlusion 9.6
443 angiodysplasia 9.6
444 agammaglobulinemia 9.6
445 papilloma 9.6
446 epidermolysis bullosa 9.6
447 acute pancreatitis 9.6
448 myelitis 9.6
449 fibrosarcoma 9.6
450 pseudohermaphroditism 9.6
451 pleural empyema 9.6
452 gastritis 9.6
453 spindle cell sarcoma 9.6
454 radiculopathy 9.6
455 epidermolysis bullosa acquisita 9.6
456 pustulosis of palm and sole 9.6
457 hepatitis e 9.6
458 rhinitis 9.6
459 ludwig's angina 9.6
460 ovarian cyst 9.6
461 hemangioblastoma 9.6
462 volkmann contracture 9.6
463 aortic valve insufficiency 9.6
464 inferior myocardial infarction 9.6
465 cll/sll 9.6
466 pulmonary valve stenosis 9.6
467 t-cell leukemia 9.6
468 peptic ulcer disease 9.6
469 childhood leukemia 9.6
470 myocarditis 9.6
471 polycythemia 9.6
472 hodgkin's lymphoma, lymphocytic-histiocytic predominance 9.6
473 herpes simplex 9.6
474 vasculitis 9.6
475 myeloid leukemia 9.6
476 psoriasis 9.6
477 evans' syndrome 9.6
478 amyloidosis 9.6
479 episodic ataxia 9.6
480 polyarteritis nodosa 9.6
481 toxoplasmosis 9.6
482 hypereosinophilic syndrome 9.6
483 albinism 9.6
484 anca-associated vasculitis 9.6
485 arachnoid cysts 9.6
486 cytokine deficiency 9.6
487 degos 'en cocarde' erythrokeratoderma 9.6
488 heparin-induced thrombocytopenia 9.6
489 mallory-weiss syndrome 9.6
490 myasthenia gravis congenital 9.6
491 mycobacterium avium complex infections 9.6
492 paraneoplastic neurologic disorders 9.6
493 pseudomyotonia 9.6
494 pustular psoriasis 9.6
495 pyogenic granuloma 9.6
496 soft tissue sarcoma 9.6
497 splenomegaly 9.6
498 talipes equinovarus 9.6
499 transposition of the great arteries 9.6
500 transverse myelitis 9.6
501 xp22.3 microdeletion syndrome 9.6
502 color vision deficiency 9.6
503 hereditary hypophosphatemic rickets 9.6
504 pain - chronic 9.6
505 cerebral aneurysms 9.6
506 encephalopathy 9.6
507 acute transverse myelitis 9.6
508 mandibular arteriovenous malformation 9.6
509 isolated split hand-split foot malformation 9.6
510 juvenile nasopharyngeal angiofibroma 9.6
511 tafro syndrome 9.6
512 diffuse alveolar hemorrhage 9.6
513 thrombophilia due to activated protein c resistance 9.5 F2 F3 F8 F9 VWF
514 inherited blood coagulation disease 9.2 F2 F3 F7 F8 F9 VWF
515 blood coagulation disease 9.2 F2 F3 F7 F8 F9 VWF

Graphical network of the top 20 diseases related to Hemophilia:



Diseases related to Hemophilia

Symptoms & Phenotypes for Hemophilia

UMLS symptoms related to Hemophilia:


angina pectoris, edema, chest pain

GenomeRNAi Phenotypes related to Hemophilia according to GeneCards Suite gene sharing:

27 (showing 21, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.68 TFPI
2 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.68 TFPI
3 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.68 F2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.68 F2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.68 F2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.68 F2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.68 F9
8 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.68 F2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.68 F9
10 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.68 TFPI
11 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.68 F2 F9 TFPI
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.68 TFPI
13 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.68 F9
14 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.68 TFPI
15 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.68 F9
16 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.68 F9
17 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.68 F2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-44 9.68 F9
19 Increased shRNA abundance (Z-score > 2) GR00366-A-5 9.68 TFPI
20 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.68 F9
21 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.68 F9

MGI Mouse Phenotypes related to Hemophilia:

47 (showing 3, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.63 F2 F3 F7 F9 TFPI VWF
2 homeostasis/metabolism MP:0005376 9.61 F2 F3 F7 F8 F9 LMAN1
3 mortality/aging MP:0010768 9.23 F2 F3 F7 F8 F9 LMAN1

Drugs & Therapeutics for Hemophilia

PubMedHealth treatment related to Hemophilia: 64

The main treatment for hemophilia is called replacement therapy. Concentrates of clotting factor VIII (for hemophilia A) or clotting factor IX (for hemophilia B) are slowly dripped or injected into a vein. These infusions help replace the clotting factor that's missing or low.Clotting factor concentrates can be made from human blood. The blood is treated to prevent the spread of diseases, such as hepatitis. With the current methods of screening and treating donated blood, the risk of getting an infectious disease from human clotting factors is very small.To further reduce the risk, you or your child can take clotting factor concentrates that aren't made from human blood. These are called recombinant clotting factors. Clotting factors are easy to store, mix, and use at home—it only takes about 15 minutes to receive the factor.You may have replacement therapy on a regular basis to prevent bleeding. This is called preventive or prophylactic (PRO-fih-lac-tik) therapy. Or, you may only need replacement therapy to stop bleeding when it occurs. This use of the treatment, on an as-needed basis, is called demand therapy.Demand therapy is less intensive and expensive than preventive therapy. However, there's a risk that bleeding will cause damage before you receive the demand therapy.

Drugs for Hemophilia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 267, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable
2
Anti-inhibitor coagulant complex Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable
3
Tranexamic Acid Approved Phase 4,Phase 3,Not Applicable 1197-18-8 5526
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3 22916-47-8 4189
5
rituximab Approved Phase 4,Phase 3,Phase 2 174722-31-7 10201696
6
tannic acid Approved Phase 4,Phase 3,Phase 1 1401-55-4
7
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
8
Zalcitabine Approved, Investigational Phase 4,Phase 3,Phase 2 7481-89-2 24066
9
Stavudine Approved, Investigational Phase 4,Phase 3,Phase 2 3056-17-5 18283
10
Zidovudine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 30516-87-1 35370
11
Indinavir Approved Phase 4,Phase 3,Phase 2,Not Applicable 150378-17-9 5362440
12
Didanosine Approved Phase 4,Phase 3,Phase 2,Phase 1 69655-05-6 50599
13
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2 134678-17-4 60825
14
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
15
Ropivacaine Approved Phase 4 84057-95-4 175805 71273
16
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
17
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2 198153-51-4 5360545
18
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1 36791-04-5 37542
19
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
20
Phylloquinone Approved, Investigational Phase 4,Phase 3 84-80-0
21 Menaquinone Approved, Investigational Phase 4,Phase 3 1182-68-9
22
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
23
Apixaban Approved Phase 4 503612-47-3 10182969
24
Dalteparin Approved Phase 4,Phase 3 9005-49-6
25
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 46507594 772
26
Menadione Approved, Nutraceutical Phase 4,Phase 3 58-27-5 4055
27
Serine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 56-45-1 5951
28
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 22737-96-8, 11103-57-4 9904001 445354
29 Coagulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Factor VIII Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Hemostatics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33 Antibodies Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
35 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Antifungal Agents Phase 4,Phase 3
42 Deamino Arginine Vasopressin Phase 4,Phase 2,Phase 1,Not Applicable
43 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Not Applicable
44 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1
45 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1
46 Antibodies, Bispecific Phase 4,Phase 3,Phase 1
47
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Reverse Transcriptase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
51 Antifibrinolytic Agents Phase 4,Phase 3,Not Applicable
52 Hylan Phase 4
53 triamcinolone acetonide Phase 4
54 Triamcinolone hexacetonide Phase 4
55 Protective Agents Phase 4,Phase 3,Not Applicable
56 Triamcinolone diacetate Phase 4
57 Adjuvants, Immunologic Phase 4,Not Applicable
58 Viscosupplements Phase 4,Not Applicable
59 Interferon-alpha Phase 4,Phase 2
60 interferons Phase 4,Phase 3,Phase 2
61 Complement Factor I Phase 4
62 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
63 Steroid Synthesis Inhibitors Phase 4
64 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
65 Hormone Antagonists Phase 4,Phase 3,Phase 2
66 Cytochrome P-450 CYP2C19 Inhibitors Phase 4,Phase 2
67 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
68 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 2
69 Natriuretic Agents Phase 4,Phase 2,Phase 1,Not Applicable
70 arginine Phase 4,Phase 2,Phase 1,Not Applicable
71 Arginine Vasopressin Phase 4,Phase 2,Phase 1,Not Applicable
72 Vasopressins Phase 4,Phase 2,Phase 1,Not Applicable
73 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
74 Antithrombins Phase 4,Phase 3,Phase 2,Phase 1
75 Vitamin K Phase 4,Phase 3
76 naphthoquinone Phase 4,Phase 3
77 Vitamins Phase 4,Phase 3,Not Applicable
78 Antithrombin III Phase 4,Phase 3,Phase 2,Phase 1
79 Serine Proteinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
80 Factor Xa Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
81 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
82 glucocorticoids Phase 4,Phase 3,Phase 2
83 Vaccines Phase 4,Phase 2
84 calcium heparin Phase 4,Phase 3
85 retinol Phase 4
86 Retinol palmitate Phase 4
87 Heparin, Low-Molecular-Weight Phase 4,Phase 3
88 Antibodies, Monoclonal Phase 4,Phase 2
89
Dapsone Approved, Investigational Phase 3 80-08-0 2955
90
Atovaquone Approved Phase 3 95233-18-4 74989
91
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
92
leucovorin Approved Phase 3 58-05-9 143 6006
93
Warfarin Approved Phase 3 81-81-2 54678486 6691
94
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
95
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
96
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
97
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
98
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
99
Edoxaban Approved Phase 3,Phase 1 480449-70-5
100
Fondaparinux Approved, Investigational Phase 3 104993-28-4
101
Enoxaparin Approved Phase 3 9005-49-6 772
102
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
103
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
104 Fibrinolytic Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
105 Ophthalmic Solutions Phase 2, Phase 3
106 Plasminogen Phase 2, Phase 3,Phase 3,Phase 1
107 Immunosuppressive Agents Phase 3,Phase 2
108 Autoantibodies Phase 2, Phase 3
109 BAX 855 Phase 3,Phase 2,Phase 1
110 Immunoglobulin Fc Fragments Phase 3,Phase 1,Early Phase 1
111 HIV Antibodies Phase 3
112 Antiprotozoal Agents Phase 3
113 Folate Phase 3
114 Antimalarials Phase 3
115 Anti-Bacterial Agents Phase 3,Not Applicable
116 Folic Acid Antagonists Phase 3
117 Anti-Infective Agents, Urinary Phase 3
118 Vitamin B Complex Phase 3
119 Antiparasitic Agents Phase 3
120 Renal Agents Phase 3
121 Vitamin B9 Phase 3
122 Peripheral Nervous System Agents Phase 3,Phase 2,Not Applicable
123 Thromboplastin Phase 3,Phase 2,Phase 1
124 Lipoprotein-associated coagulation inhibitor Phase 3,Phase 2,Phase 1
125 Antineoplastic Agents, Alkylating Phase 3,Phase 2
126 Alkylating Agents Phase 3,Phase 2
127 Neuroprotective Agents Phase 3
128 Gastrointestinal Agents Phase 3,Phase 2
129 Antiemetics Phase 3
130 Autonomic Agents Phase 3
131 Methylprednisolone Acetate Phase 3
132 Prednisolone acetate Phase 3
133 Antibodies, Blocking Phase 3
134 pyruvate Phase 3
135 PENTA Phase 3
136 Antibodies, Antiphospholipid Phase 3
137
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
138
Oprelvekin Approved, Investigational Phase 2 145941-26-0
139
Icodextrin Approved, Investigational Phase 2 337376-15-5
140
Sofosbuvir Approved Phase 2 1190307-88-0 45375808
141
Ledipasvir Approved Phase 2 1256388-51-8 67505836
142
Nevirapine Approved Phase 2,Phase 1 129618-40-2 4463
143
Abacavir Approved, Investigational Phase 2 136470-78-5 441300 65140
144
Efavirenz Approved, Investigational Phase 2 154598-52-4 64139
145
Acyclovir Approved Phase 2 59277-89-3 2022
146
Hydroxyurea Approved Phase 2 127-07-1 3657
147
Adefovir dipivoxil Approved, Investigational Phase 2,Not Applicable 142340-99-6 60871
148
Nelfinavir Approved Phase 2,Not Applicable 159989-64-7 64143
149
Aspirin Approved, Vet_approved Phase 2,Not Applicable 50-78-2 2244
150
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662